A Craig Lockhart
Overview
Explore the profile of A Craig Lockhart including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
94
Citations
3884
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Terrero G, Lockhart A
Curr Oncol Rep
. 2020 Aug;
22(11):112.
PMID: 32803457
Purpose Of Review: Immunotherapy and tumor microenvironment have been at the forefront of cancer research over the past several decades. Here, we will review the role of immunotherapy in advanced...
12.
Catenacci D, Kang Y, Park H, Uronis H, Lee K, Ng M, et al.
Lancet Oncol
. 2020 Jul;
21(8):1066-1076.
PMID: 32653053
Background: Margetuximab, a novel, investigational, Fc-engineered, anti-HER2 monoclonal antibody, is designed to more effectively potentiate innate immunity than trastuzumab. We aimed to evaluate the safety, tolerability, and antitumour activity of...
13.
Dang H, Krasnick B, White B, Grossman J, Strand M, Zhang J, et al.
Sci Adv
. 2020 Jun;
6(24):eaay9691.
PMID: 32577507
Tumor heterogeneity and evolution drive treatment resistance in metastatic colorectal cancer (mCRC). Patient-derived xenografts (PDXs) can model mCRC biology; however, their ability to accurately mimic human tumor heterogeneity is unclear....
14.
Patel C, Goel S, Patel M, Rangachari L, Wilbur J, Shou Y, et al.
Clin Pharmacol Drug Dev
. 2020 Jun;
9(7):876-888.
PMID: 32488989
The aim of this phase 1 study was to determine the effects of sapanisertib on the heart rate-corrected QT (QTc) interval in patients with advanced solid tumors. Adult patients with...
15.
Park H, Jin R, Wang-Gillam A, Suresh R, Rigden C, Amin M, et al.
JAMA Oncol
. 2020 May;
6(8):1231-1240.
PMID: 32469386
Importance: Standard first-line regimens for patients with metastatic gastroesophageal adenocarcinomas have an approximate 40% objective response rate (ORR). The combination of leucovorin, fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) has been efficacious...
16.
Grierson P, Teague A, Suresh R, Lim K, Amin M, Pedersen K, et al.
J Gastrointest Oncol
. 2020 Mar;
11(1):61-67.
PMID: 32175106
Background: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with limited therapeutic options. We evaluated the safety and efficacy of the aminopeptidase inhibitor tosedostat with capecitabine in advanced PDAC. Methods:...
17.
Subbiah V, Puzanov I, Blay J, Chau I, Lockhart A, Raje N, et al.
Cancer Discov
. 2020 Feb;
10(5):657-663.
PMID: 32029534
mutations occur in a wide range of tumor types, and RAF inhibition has become standard in several of these cancers. Despite this progress, mutations have historically been considered a clear...
18.
Heo G, Detering L, Luehmann H, Primeau T, Lee Y, Laforest R, et al.
Mol Pharm
. 2019 Aug;
16(9):3996-4006.
PMID: 31369274
Folate receptor α (FRα) is a well-studied tumor biomarker highly expressed in many epithelial tumors such as breast, ovarian, and lung cancers. Mirvetuximab soravtansine (IMGN853) is the antibody-drug conjugate of...
19.
Zhou X, Lockhart A, Fu S, Nemunaitis J, Sarantopoulos J, Muehler A, et al.
J Clin Pharmacol
. 2019 Apr;
59(9):1204-1215.
PMID: 30985952
This clinical trial was designed to evaluate the effect of moderate or severe hepatic impairment on the single-dose pharmacokinetics (PK) of the investigational anticancer agent, alisertib, in adult patients with...
20.
Weekes C, Lockhart A, Lee J, Sturm I, Cleton A, Huang F, et al.
Int J Cancer
. 2019 Apr;
145(9):2450-2458.
PMID: 30958892
Regorafenib 160 mg orally once daily (QD) 3 weeks on/1 week off is approved in colorectal cancer, gastrointestinal stromal tumors and hepatocellular carcinoma. We established the safety and pharmacokinetics (PK)...